PRCM
LGND icon

Pine River Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Pine River Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-29,976
Closed -$1.44M – 738
2015
Q1 		$1.44M Buy
+29,976
New +$1.15M 0.02% 351

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pine River Capital Management's LGND Position: Q2 2015 in Review

Pine River Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2015, closing a stake of 29,976 shares — an estimated $1.44M sold.

Pine River Capital Management first reported a position in LGND in Q1 2015 and held it in 1 quarter. The position peaked at $1.44M in Q1 2015. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

  • Pine River Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Pine River Capital Management sold 29,976 Ligand Pharmaceuticals shares in Q2 2015, an estimated $1.44M.
  • Pine River Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Pine River Capital Management's Ligand Pharmaceuticals position peaked at $1.44M in Q1 2015.
  • 215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Pine River Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.